Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman
Hagens Berman said Aardvark Therapeutics’ (NASDAQ: AARD) shares fell $2.16, or 32%, on May 15, 2026 after the FDA placed a clinical hold on the company’s ARD-101 program for Prader-Willi syndrome. It also cited a March 2 2026 drop of $7.02, or 56%, after Aardvark paused its Phase 3 HERO trial. The firm is investigating Aardvark’s disclosures and FDA communications.
How this was made
The 30-second read
Why it matters
The FDA hold applies to all ongoing studies under the IND, including Phase 3 HERO and the Phase 3 open-label extension, increasing uncertainty around enrollment, timelines, and probability-weighted outcomes.
Market read
A full clinical hold on the company’s lead IND is a direct, fundamental risk reset and explains the large drawdown cited in the article.
What to watch
The article is framed around a law-firm investigation and prior trial pause; traders should separate the FDA hold’s operational implications from allegations about disclosure propriety.
Background
The article describes two major negative catalysts for Aardvark: a March 2 Phase 3 HERO trial pause tied to reversible cardiac observations, followed by a May 14 FDA full clinical hold on the ARD-101 IND.
Ticker impact
Aardvark Therapeutics shares fell 32% after the FDA placed a full clinical hold on its ARD-101 IND, including HERO and OLE trials.
Bearish near term, with volatility elevated around any FDA communications or trial restart updates.
The article cites a full IND clinical hold affecting all ongoing studies under the IND, which directly impairs the company’s primary development pathway and is tied to a large, recent selloff.
Market effects
Reinforces heightened regulatory scrutiny risk for rare-disease gene or small-molecule programs, potentially pressuring sentiment across similar pre-approval biotech names.
Limited direct regional spillover; primarily impacts US small-cap biotech risk appetite.
Moderate, as FDA holds can influence global investor perception of development timelines for comparable assets.
Counterpoint
A clinical hold does not equal IND rejection; if the hold is protocol-specific, the market may over-discount the probability of eventual resolution.
Key entities
- companyAardvark Therapeutics
NASDAQ-listed biotech whose ARD-101 program is under an FDA full clinical hold.
- regulatorFDA
Placed a full clinical hold on Aardvark’s ARD-101 IND, halting ongoing HERO and OLE studies.
- law_firmHagens Berman
Plaintiffs’ rights firm soliciting investors regarding potential securities-law disclosure issues.
